Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
7 participants
INTERVENTIONAL
2017-10-30
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LDR vs. HDR Brachytherapy for Prostate Cancer
NCT03426748
HDR Focal: Feasibility Study
NCT02918253
Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial
NCT07300566
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
NCT01605097
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
NCT02692105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LDR/HDR
MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
LDR/HDR
Focal LDR to dominant lesion with whole gland 19 Gy HDR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LDR/HDR
Focal LDR to dominant lesion with whole gland 19 Gy HDR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single PIRADS 4 or 5 lesion on multiparametric MRI
* T1c-T2b on rectal exam
* Gleason 3+3 and PSA \< 20ng/mL
* Gleason 3+4 and PSA \<10ng/mL
* Less than 50% of the cores positive in an untargeted prostate biopsy.
* Prostate volume \< 60 cc
Exclusion Criteria
* Previous trans-urethral resection of prostate (TURP)
* Previous or current use of androgen deprivation
* Baseline International Prostate Symptom Score (IPSS) \> 15
* Evidence of distant or nodal metastasis
* Disease that contraindicates treatment with radiation (e.g connective tissue disease)
* Unsuitable for anesthesia due to comorbidity
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunnybrook Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DELIGHT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.